In Lausanne, Switzerland on February 23, 2026, ADC Therapeutics SA (NYSE: ADCT), a prominent company specializing in antibody drug conjugates (ADCs), revealed an update to its royalty purchase agreement. This amendment signifies a significant development for the company as it solidifies its position as a global leader in the field. The specific details of the amendment, including the entities involved and the revised terms, were not disclosed in the announcement. This news highlights the company's ongoing efforts to expand its presence and influence in the pharmaceutical industry.